Kalyan R. Bhamidimarri MD – FDA 483, Jan 16, 2020
An FDA inspection of Kalyan R. Bhamidimarri MD, a clinical investigator in Miami, revealed significant deficiencies in the conduct of investigational drug studies. The principal investigator failed to provide adequate oversight, leading to a subject receiving additional study drug and a prohibited medication, which contributed to pulmonary edema and death. Additionally, there were failures to promptly and accurately report serious adverse events and protocol deviations to both the sponsor and the Institutional Review Board (IRB).
ID · 45825aa8-3ac8-42cf-b803-da20fca57c7f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.